4 November 2024

Botanix Pharmaceuticals Limited
Chairman's Address

Good morning and welcome to you all. Thank you for joining us at the Botanix Pharmaceuticals Annual General Meeting. Although we would prefer to be there to greet you in person, CEO Dr Howie McKibbon, Director Bill Bosch and Executive Director Matt Callahan and I know you are in the capable hands of Directors Danny Sharp and Stewart Washer today in Perth. We wish to acknowledge and thank our valued investors for the strong support shown to Botanix and the resolutions to be presented today.

Since our AGM last year, *Sofdra*™ has received US FDA approval and we have completed the transformation of Botanix into a commercial-ready dermatology company, on the cusp of generating first sales as the *Sofdra* Patient Experience Program is finalised for launch. The program will provide initial patient feedback on the robust telehealth and fulfillment platform developed by Botanix, to speed Sofdra into the hands of patients.

This progress would not have been possible without the exceptional team of Botanix employees led by our CEO, Dr Howie McKibbon, along with support from our Board members and valued consultants. In a year, we have grown from being a team of less than 10 people to more than 25, including proven leadership in sales management, marketing management, sales training, sales operations and other functions that will support the commercialisation of *Sofdra.* This skilled team has extensive experience in the launch of new dermatology products, with more than 30 product launches amongst them.

The Botanix organization will soon expand to greater than double in size with the addition of 27 sales professionals, that will begin calling on dermatologists following the sales launch meeting less than two months from today. Utilizing a highly focused sales force of modest size, we can reach the large majority of regular prescribers of products for hyperhidrosis.

Sofdra represents a significant opportunity for Botanix, as the only new chemical entity developed specifically for the treatment of excessive underarm sweating, also known as axillary hyperhidrosis. We are poised to enter this underserved market of ten million sufferers with a new option, designed to address a long unmet need.

At the same time that Botanix sales professionals enter the marketplace, the Company will begin direct to consumer advertising, to extend our reach beyond the dermatologists' office to unserved patients around the US and drive them to our telehealth solution.

Engagement with patients and dermatologists is well underway with the two groups showing great anticipation for the launch of Sofdra. Botanix completed numerous hour-long in-depth interviews with both audiences to gain insights and perfect its marketing messages. In addition,

the Botanix leadership team recently completed four days of individual meetings with high prescribers and key opinion leaders at Fall Clinical Dermatology, the leading independent medical conference for dermatologists. Botanix has deep rooted relationships with leading dermatologists, including those who speak regularly at conferences, and is in regular communication to ensure that they are knowledgeable about Sofdra.

Separately our Payer team has been very active in executing the first contracts with Payers. Along with the contracts in final negotiation for both Commercial and Medicaid patients our coverage is playing out as we expected, reflecting more than a year of work with Payers agreeing on pricing, rebates and access terms.

It has been an exciting time for Botanix, and this is only the beginning. We invite you to join us as we seek to build the leading independent dermatology company in the world.

Now I will ask the team to walk through a quick overview of our progress.

Release authorised by

Vince Ippolito
Executive Chairman

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US) which has received FDA approval for its lead product *Sofdra* for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition

To learn more please visit: http://www.botanixpharma.com/

For more information, please contact:

General enquiries
Corporate Communications
Botanix Pharmaceuticals
P: +61 8 6555 2945
investors@botanixpharma.com

Investor enquiries
Hannah Howlett
WE Communications
P: +61 450 648 064
hhowlett@we-worldwide.com

Media enquiries
Haley Chartres
H^CK
P: +61 423 139 163
haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs, the Company's ability to obtain marketing approvals for is product candidates, the expected timing and/or results of regulatory approvals and the outcome and effects of *Sofdra* and the market for *Sofdra*. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Sofdra Important Safety Information & Indication

Indication

Sofdra (sofpironium) topical gel, 12.45% is a prescription anticholinergic medicine used on the skin (topical) to treat excessive underarm sweating (primary axillary hyperhidrosis) in adults and children 9 years of age and older.

IMPORTANT SAFETY INFORMATION

***Sofdra* is for use on the skin in the underarm area only. Wash your hands right away after you apply *Sofdra*. Do not touch your underarms after applying *Sofdra*. *Sofdra* is flammable. Avoid heat and flame while applying *Sofdra*.**

Who should not use *Sofdra*?

Do not use *Sofdra* if you have certain medical conditions that can be made worse by taking an anticholinergic medicine such as glaucoma, severe ulcerative colitis (UC) or certain other serious bowel problems associated with severe UC, myasthenia gravis, and Sjogren's syndrome.

What should I tell my healthcare provider before using *Sofdra*?

- **Tell your healthcare provider about all of your medical conditions,** including bladder or kidney problems, problems passing urine, if you are pregnant or breastfeeding, or plan to become pregnant or breastfeed. It is not known if *Sofdra* will harm your unborn baby or pass into your breast milk.
- **Tell your healthcare provider about all the medicines you take,** including prescription and over-the-counter medicines, especially any anticholinergic medicines.

What are possible side effects of *Sofdra*?

Serious side effects may include:

- **Blurred vision.** Stop using *Sofdra*, call your healthcare provider right away, and do not drive or operate machinery or do hazardous work until your vision is clear.
- **New or worsened urinary retention.** Stop using *Sofdra* and call your healthcare provider right away if you experience difficulty urinating, urinating frequently, urination in a weak stream or drips, full bladder or difficulty emptying your bladder.

The most common side effects of *Sofdra* include dry mouth; blurred vision; pain, redness, swelling, itching, and irritation in the underarm area; dilation of the pupils of your eyes (mydriasis); and problems with urination. These are not all of the possible side effects of *Sofdra*. Call your doctor for medical advice about side effects.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Botanix at 1-866-763-6337.

Keep *Sofdra* and all medicines out of the reach of children.